The Prohibition of Puberty Suppression in the Treatment of Gender Dysphoria – A Problematic Regulatory Exceptionalism

This article examines the legal and regulatory processes that led to the prohibition of prescribing puberty-suppressing hormones (GnRHa) for treating gender dysphoria in adolescents in the United Kingdom. Through a reconstruction of the timeline from the Cass Review to the 2024 emergency and permanent Orders under the Medicines Act 1968, we show that the measures taken were exceptional and extended far beyond established regulatory practice. Although framed as responses to safety concerns, the Orders – combined with NHS England policies and regulatory amendments – operate as a de facto universal prohibition, despite ostensibly applying only to private prescriptions. We demonstrate that the government’s actions diverged significantly from the advice of the Commission on Human Medicines, whose assessment supported regulated off-label prescribing and warned of the harms of criminalisation and treatment barriers. The article argues that the process exhibits notable irregularities, including extraordinary use of emergency powers, misrepresentation of expert advice and insufficient candour in communicating the scope and consequences of the ban.